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Coichicine. an nntimitogenic agent, has shown promise in prevent-
ing restenosis after coronary angioplasty in experimental animal
models. A prospective trial was conducted involving 197 patients
randomized in a 2 :1 fashion to treatment with oral calVid,ne,
0.6 mg twice daily (130 patients), or placebo (67 patients) for 6
months after elective coronary angioplasty . Treatment in all
patients began between 12 h before angioplasty and 24 h after
angioplasty. Compliance monitoring revealed that 96% of all
prescribed pills were ingested . Demographic characteristics were
similar in eolchkine. and placebo-treated groups. A mean of 2.7
lesions/patient were dilated. Side effects resulted in a 6 .9%
dropout rate in the eulchicine-treated patients .
Complete quantitative angiographic follow-up was obtained in
145 patients (74%) with 393 dilated lesions . Quantitative anglo .
graphic measurements were obtained in two orthogonal views at
All currently available methods for percutaneous coronary
revascularization (including balloon dilation, atherectomy,
laser photoablation and inlraluminal stenting) cause signifi-
cant endovascular trauma. The subsequent reparative re-
sponse involves myointimal proliferation that results in a
significant renarrowing or restenosis ip. 304% to 4092 of
lesions by 6 months after angioplasty (1) . The stimuli for the
smooth muscle cell proliferation involve mechanical and
rheologic factors in addition to heterogeneous growth factors
emanating from inflammatory cells and elements of the
coagulation system (2,3) . The majority of restenosis trials
performed to date have attempted to modify a single com-
ponent of this complex redundant system . The failure of any
single pharmacologic agent to consistently reduce the reste-
nosis rate after coronary angioplasty is somewhat predict-
able in this context .
This exuberant, maladaptive smooth muscle cell prolifer-
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baseline before ngioplasty, and immediately and at 6 months after
angioplasty . The quantitative mean lumen diameter stenosis be-
fore angioplasty was 67% both in the 152 lesions in the placebo-
treated group and in the 241 lesions in the cokbkitle-treated
group; this value was reduced to 24% immediately after angio-
plasty in the iesions in limb treatment groups.
At the 6-month angiogrnm, lesions had restenosed to 47%
lumen diameter narrowing in the placebo-treated group cnpared
with 46% in the cokldcine-treated group (p = NS). Forty-one
percent of cotchieuse-treated patients developed restenosis in at
least one lesion compared with 45% of the placebo-treated group
(p = NS). In coaefusion, calchicine was ineffective fur preventing
restenosis after coronary angioplasty.
(J Am Coll Cardiol 1992;O9:1597-1600)
ation has prompted some investigators to liken restenosis to
a neoplastic process (4,5). The term "malignant restenosis"
has been used (6) to describe a syndrome characterized by
rapid, refractory recurrences after repeated attempts at
perculaneous coronary revascularization. When viewed
from this perspective, the use of antimitogenic or antineo-
plastic agents is one of the most promising avenues of
exploration in the search for a solution to the complex
problem of restenosis .
Coichicine is an antimitogenic agent that binds to tubulin,
disrupting spindle formation and resulting in the metaphase
arrest of cell division . Colchicine has been shown to inhibit
chemotaxis (7,S), collagen formation (9), muscle ce!! prolif-
eration and platelet aggregation (10,11). In experimental
animal models. this agent has prevented or reduced the
formation of atherosclerotic plaques (12,13) . Coichicine has
also been effective in preventing myointimal proliferation
after balloon arterial injury of the iliac artery in an athero-
sclerotic rabbit model (14) and has been reported to be
effective in reducing fibroblastic proliferation in a patient
with incipient hepatic cirrhosis (15)
.
Colchicine has not been
used previously in a clinical trial for the prevention of
restenosis after coronary angioplasty .
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Methods
Study design. The study was designed as a double-blind
randomized trial. The patients were randomized in a 2:1
fashion to treatment with oral colchicine, 0 .5 mg twice daily,
or placebo, one tablet twice daily . The 2 . 1 randomization
scheme was used to maximize the number of patients treated
with active drug and to encourage patient enrollment while
preserving the statistical advantages of a randomized design
.
Treatment started within 24 h of angioplasty
. Twenty-four
percent of patients received one dose of colchicine or
placebo before angioplasty ; the remaining 76% of patients
received their first dose within the 1st 24 h after angioplasty .
Treatment was continued for 6 months or until the study end
point (angiographic follow-up) was achieved .
Patients were scheduled for routine follow-up office visits
at 3 and 6 months, at which time baseline laboratory studies
were repeated. Laboratory work included a hematology
profile ; liver function tests, and measurements of serum
creatinine, blood urea nitrogen, total cholesterol, triglycer-
ides and high-(HDL) and low-(LDL) density lipoprotein
levels . An exercise thallium stress test was performed at 3
months . Coronary arleriography was performed before an-
gioplasty, immediately after angioplasty and at 6-month
follow-up or earlier if the patient had recurrent angina or a
markedly abnormal thallium stress test .
Selection of patients . rrligibiiity criteria for entry into the
trial were 1) successful elective coronary angioplasty ;
2) single or multivessel angioplasty ; 3) bypass graft angio-
plasty ; 4) angioplasty of previously undiluted (new) and
restenosed lesions ; 5) angioplasty performed for silent isch-
emia and stable or unstable angina pectoris. Exclusion
criteria we-e 1) direct angioplasty for acute myocardial
infarction; fl) unsuccessful coronary angioplasty ; 3) pre-
menopausal women ; 4) baseline leukopenia
; 5) active peptic
ulcer disease ; 6) active diarrhea ; 7) creatinine ?2.5 mg/dI at
baseline ; 8) known colchicine intolerance
. Successful angio-
plasty was defined as the reduction of the dilated lesion to
m50% lumen diameter stenosis without documented acute
reocclusion during the hospital stay . The research protocol
was approved by the Institutional Review Board for Human
Research at St. Luke's Hospital, Kansas City, Missouri
.
Informed consent was obtained from all patients before
study enrollment.
Coronary angiographic measurements. The primary end
point of the trial was angiographic restenosis . Angiographic
measurements were made in a semiquantitative fashion by
using an electronic caliper that was accurate to 0 .01 mm.
Lesion measurements, expressed as the minimal relative
lumen diameter stenosis, were obtained by measuring each
dilated lesion and adjacent angiographically normal segment
three times in each of two orthogonal views
. The relative
lumen diameter stenosis was defined as the difference be-
tween the mean lumen diameter measurements of the normal
segment and the dilated lesion divided by the mean lumen
diameter of the normal segment
. The measurements were
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Table 1 . Demographic Characteristics of Patients Treated With
Cdchicine ur Placebo
There were no significant differences between groups. Unless otherwise
indicated all values indicate number of patients . Class
IV =
Canadian
Cardiovascular society functional class IV ; LVEF = lea ventricular ejection
fraction; pt = patient .
taken on each lesion before angioplasty, immediately after
angioplasty and at the 6-month follow-up study .
Statistical analysis. The study protocol called for analy-
sis of the angiographic data by two separate statistical
methods . In one model, restenosis was evaluated as a
continuous variable . In this noncategoric model, the stenosis
measurements in each of the two groups were compared
before angioplasty, immediately after angioplasty and at the
time of the 6-month angiographic follow-up . The second
method used the more traditional approach of analyzing
restenosis as a dichotomous function . In this model, reste-
nosis was defined as a return to m70% !omen diameter
stenosis at the time of the follow-up study and a loss of
>50 of the initial gain with angioplasty . When this defini-
tion was used, restenosis was evaluated categorically as a
binary outcome for the presence or absence of restenosis.
Data were analyzed with chi-square analysis and a Stu-
dent t test where appropriate . Statistical significance was
defined asp s 0 .05 .
Results
Demographic data (Table 1) . With the 2:1 randmnization
scheme, 130 patients (66% of the total group of 197 patients)
were randomized to colchicine treatment and 67 patients
(34%) to placebo treatment . The groups were very closely
matched with respect to all major demographic characteris-
tics . In the colchicine group, 2 .7 lesions/patient were eilated ;
in the placebo group, 2 .9 .
Adverse effects (Table 2). Adverse drug effects occurred
more frequently in colchicine- than in placebo-treated pa-
tients . Twenty-eight percent of colchicine-treated patients
developed diarrhea that was often refractory and resulted
in discontinuation of the drug in nine patients (7% dropout
rate) . Death occurred during the follow-up period in op>
colchicine-treated patient and in two placebo-treated pa-
dents (p = NS) .
Angiographic follow-up . Complete angiographic fol-
low-up was obtained in 145 of the 197 patients, yielding an
Cokhicine
(a = 130; 66%)
Placebo
lv = 67 ; 3470
Men 111 (85%) 58(87%)
Mean age (yr1 59 62
Prior coronary bypass surgery 34(761/0 17(25%)
LVEF <_40% 9 (7%)
5(8-)
Class IV angina 52 (409t) 26(39%)
Diabetes 16(12%) 8 (12%)
Cholesterol lmg/dl) 213 208
Lesions dilated/pt 2 .7 2 .9
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Table 2
. Adverse Drug Effects in 197 Patients Trealcd
W ;,)
Colchicine or Placebo
'p = 0.0001 . Tp = 0.15: other differences are nor sienificanr . t3nleas
otherwise indicated. all values indicate number of patient, .
angiographic follow-up rate of 74% . Follow-up coronary
angiography was performed a mean of 5 .5 months after
angioplasty . Angoographic follow-up was not obtained in 52
patients because of death in 3 patients . dropout due to
treatment side effects in 10 (9 receiving colchicine . I receiv-
ing placebo) and refusal to undergo elective follow-up cath-
eterization in the remaining 39 . In the 184 patients eligible for
the 6-month cardiac catheterization (excluding patients who
died or were intolerant to study medication) . the follow-up
rate was 79% (83% in placebo and 77% in colchicine groups .
p = NS). In the 145 patients with complete angiographic
follow-up, initial angiographic success was achieved in 393
(98%) of the 401 lesions dilated .
The restenosis rate was 22%desion in t t")& the colchicine-
and placebo-treated broups
. Foriy-one percent of colchicine-
treated patients had restenosis in at least one lesion com-
pared with 45% of the placebo-treated group (p = NS) . The
mean lumen diameter s eno .. essentially h3emi^al i
the two groups at baseline,
s
immediately after angioplasty
and at 6-month follow-up (Fig . 1) .
Thallium stress test data . A 3-month postangioplasty
exercise thaitium-201 stress test was performed in 118 (63%)
Figure 1 . The mean coronary lumen diameter stenoses of the
placebo- and colchicine-treated groups were throst identical before
angioplasty (Pre-PICA), immediately after angioplasty (Post-
PfCA) and at 6-month angiographic follow-up in
= NS)
. PTCA =
percataneous transluminal coronary angioplasty.
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of patients . Scintigraphic evidence for recurrent ischemia in
the distribution of a dilated vessel was noted in 56 (53%) of
96 segments in the colchicine-treated patients and 27 ,511%)
of 54 segments in the placebo-treated patients (p = NS) .
Recurrent ischemia on thallium stress testing was noted in
at least one dilated vessel distribution in 6690 of the 73
colchicine-treated patients and in 58% of the 45 placebo-
t •e ated patients (p = NS) .
Discussion
Previous studies. In the current study, treatment with
oral colchicine that was started at the time of coronary
angioplasty had no effect on the subsequent rate of resteno-
sis after angioplasty . In another trial (16) using colchicine
preliminary results were also negative, although that trial
used clinical nonangiographic end points. Although colchi-
cine was demonstrated to be effective in reducing intimal
proliferation after balloon injury to a rabbit iliac artery (14),
the effect was apparent only with the highest dose of the
medication. In that study, Currier et al . (14) found a reduced
rate of restenosis in animals treated with high dose
(0 .2 mg/kg per day) but not with low dose (0.02 mg/kg per
day) colchicine . In the standard 70-kg human, the high done
regimen would translate to 14 mg/day of colchicine . High
dose colchicine has been used as an aatineoplastic agent for
conditions such as leukemia (5) but was poorly tolerated
because of serious adverse effects, such as hemorrhagic
gastritis and bone marrow suppression. Although the colchi-
cine regimen in the current trial (1 .2 mg/day) was considered
to be relatively low dose, 7% of treated patients were unable
to complete the study owing to severe gastrointestinal ad-
verse effects (generally diarrhea) . The incidence of signifi-
cant diarrhea (28%) in the treated group in the current trial
suggests that the systemic antimitogenic effects were ade-
quate to interfere with gastrointestinal mucosal cell turn-
over . Furthermore, this same regimen (colchicine,
1
.2 mg/day) was reported to he effective in reducing peripor-
tal fibtnsis in the setting of incipient hepatic cirrhosis (15) .
Limitations. The lack of consistent pretreatment in the
current study is a potential limitation of the trial . However,
the artimitogenic effects of colchicine are clinically apparent
within hours of its use. Postmortem human studies (17) have
shown that the migration of smooth muscle cells from the
media to the intima occurs within the 1st 2 to 3 days after
angioplasty . The actual proliferation of these cells begins
shortly thereafter (II to 30 days after angioplasty) . Thus,
antimitotic therapy with colchicine started at the time of the
procedure should be adequate for the inhibition of subse-
quent myointimai proliferation .
Other neoplastic agents . Other neoplastic agents have
been used in experimental animal angioplasty models . The
hyperalastic smooth muscle cells responsible for the re-
stcnotic process are of mesenchvmal cell origin (18). The
chemoeherapeutic agents generally used for t mo.-s ar irg
from mesenchymal cells include methotrexate, vineristine
.
Colchicine
a = 130)
Placebo
m = 671
Diarrhea 36126301 311W
Nausealvomiting 5 (4300) 4(6Si1
Rash 211 .5301 III 530)
Dyspepsia 0 1 (15`i)
Death I (3
.801)
7 13^n1
Drop.., rein 9 (6.903) 111 .1 i
;
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cyclophosphamide and anthracycline antibiotic agents . Ac-
cordingly. the antineoplastic agents investigated so far in
animals have generally been from this group of drugs .
Combination therapy with vincristine and actinomycin U has
been evaluated in a rabbit aortic model (19) .
Short-term
therapy resulted in less smooth muscle cell hyperplasia 3
days after endothelial denudation in the rabbits treated with
antineoplastic agents. The intermediate and long-term ef-
fects of this therapy were not observed in this study
. The
effectiveness of local methotrexate therapy on intimai pro-
liferation after balloon arterial injury was evaluated by
Mailer et
a1 . (20) . After initial balloon arterial injury to the
porcine carotid artery, nethotrexate was intramurally ad-
ministered through a Wolinsky coronary infusion balloon
catheter (21). In this model, the local infusion of methotrex-
ate did not abolish or even attenuate intimal proliferation.
The use of systemic antineoplastic agents for restenosis was
also addressed by Murphy et al. (22) . In their trial utilizing a
porcine coronary restenosis model . the use of oral or intra-
muscular methotrexate or azathioprine did not inhibit intimal
proliferation and restenosis .
Clinical implications. The relatively low restenosis rate
per lesion
(22%) and per patient (43%) resulted from the use
of a "conservative" definition of restenosis (as called for by
the study protocol) . The rate of restenosis per vessel by
scintigraphic criteria on thallium-20t stress testing was sig-
nificantly higher (55%) . This finding suggests that some
lesions had become hemodyramically significant again, al-
though they had not returned to the baseline 70% lumen
diameter stenosis, and had lost at least 50% of the initial gain
with angioplasty . Additionally, many patients had more than
. dilated in a single vessel or vascular territory .
Thus, they had an increased likelihood that recurrent isch-
emia would he detected in this distribution by tomographic
thallium imaging, reflecting the additive risk of restenosis
when multiple lesions are dilated (23)
.
Conclusions, The use of colchicine, although theoretically
promising, proved ineffective in preventing restenosis after
coronary angioplasty in the current study
. Although the use of
antineoplastic and antimitogenic agents in this application
merits further consideration, therapy with higher doses and
more potent agents will be limited to some degree by frequent,
serious and even life-threatening adverse effects inherent in
such regimens . Delivery systems to allow for local applica-
tion of these agents may obviate some
of these limitations.
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